Kinloch Capital LLC bought a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 4,497 shares of the company’s stock, valued at approximately $578,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Frazier Financial Advisors LLC acquired a new position in Merck KGaA in the 2nd quarter valued at approximately $25,000. Rakuten Securities Inc. acquired a new position in shares of Merck KGaA during the second quarter worth $27,000. Solstein Capital LLC acquired a new position in shares of Merck KGaA during the second quarter worth $33,000. Burk Holdings LLC bought a new stake in shares of Merck KGaA in the second quarter worth $39,000. Finally, Bard Associates Inc. bought a new stake in shares of Merck KGaA in the second quarter worth $60,000. 0.10% of the stock is owned by institutional investors.
Merck KGaA Stock Performance
OTCMKTS MKGAF opened at $163.45 on Tuesday. The company has a market capitalization of $21.12 billion, a price-to-earnings ratio of 24.95 and a beta of 0.96. Merck KGaA has a twelve month low of $116.68 and a twelve month high of $175.56. The stock has a fifty day simple moving average of $162.78 and a 200 day simple moving average of $148.59. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27.
About Merck KGaA
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Articles
- Five stocks we like better than Merck KGaA
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
